Full Title
Pilot weight loss intervention with dual GIP/GLP-1 receptor agonist therapy in patients with endometrial cancer and obesity, overweight, with or without diabetesPurpose
People with endometrial cancer often gain weight during and after chemotherapy. Medicines to reduce the risk of an allergic reaction for people receiving chemotherapy can also raise blood sugar. Weight gain can affect overall health and cancer recovery.
Weight loss medications such as tirzepatide and semaglutide work well in people without cancer. Researchers want to see if they can help manage weight and blood sugar in people receiving chemotherapy for endometrial cancer.
If you join this study, you will give yourself an injection of tirzepatide or semaglutide once a week. You will take the medication for up to 24 weeks.
Who Can Join
To join this study, there are a few conditions. You must:
- Have endometrial cancer that has been removed and will be treated with chemotherapy at Memorial Sloan Kettering.
- Be eligible to receive weight loss medication due to being obese, having type 2 diabetes, or being overweight and having another condition.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call Dr. Angela Green’s office at 646-888-6792.